Qynapse to Present Poster Presentations and Attend the Alzheimer’s Association International Conference (AAIC) 2021 in Denver, USA and Online

/0 Comments/in , /by

QYNAPSE Inc., a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, is attending the Alzheimer’s Association International Conference 2021 (AAIC) on July 26-30, 2021 in Denver, USA and online, and will present two poster presentations on QyScore®, it’s groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings.

Read more

Qynapse to present clinical results of QyScore® for Alzheimer’s Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

/0 Comments/in , /by

QYNAPSE today announced it will present clinical data on QyScore® for Alzheimer’s disease and multiple sclerosis at the 7th Congress of the European Academy of Neurology (EAN), which is being held virtually on June 19 – 22, 2021. Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation on June 20, 2021, at 6:05 a.m. ET and Philippe Tran, R&D Scientist at Qynapse, will give an ePoster on June 20, 2021, at 1:30 p.m. ET.

Read more

Qynapse reaffirms its commitment to research in Multiple Sclerosis and is pleased to announce new projects to advance research and clinical care for MS patients

/0 Comments/in /by

Qynapse joins the global multiple sclerosis (MS) community in recognition of World MS Day to raise awareness for everyone affected by MS. Emphasizing the World MS Day 2021 theme, MS Connections, Qynapse has been engaged for years in contributing to connect MS patients to MS research, especially in the field of neuroimaging innovation.

Read more

QYNAPSE to Present at Sachs 4th Annual Neuroscience Innovation Forum

/0 Comments/in , /by

QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.

Read more

Qynapse joins Decentralized Trials & Research Alliance (DTRA) to democratize and accelerate clinical trials

/0 Comments/in /by

QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

Read more

QYNAPSE to sponsor and exhibit at the 106th RSNA Annual Meeting and present its latest AI-neuroimaging advancements, which are transforming care for patients with brain disorders

/0 Comments/in /by

QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.

Read more

QYNAPSE appoints Matt Ullum as Chief Commercial Officer to drive and accelerate its growth globally

/0 Comments/in /by

QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.

Read more

QyPredict®: an AI prediction technology for optimizing patient selection in clinical trials to be presented at the CTAD Conference by QYNAPSE

/0 Comments/in , /by

QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.

Read more

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases

/0 Comments/in /by

QYNAPSE today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval – to form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

Read more

World Alzheimer’s Day: Neuroimaging and artificial intelligence offer new opportunities for patients

/0 Comments/in /by

Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer’s. “By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer’s disease.”

Read more